Boditech Med
Boditech Media
-
Boditech Med, Q1 2024 Sales Reach $21.6 Million (33.1 Billion Won) ... Up 12.3% YoY
Consolidated sales for Q1 2024 amounted to $21.6 million (33.1 billion won), with operating profit recorded at $4.2 million (5.9 billion won).
Learn More -
Boditech Med Acquires 3.03% Stake in 4TEEN4, a German Developer of Products for Cardiogenic Shock
Planned launch of DPP3 on-site diagnostic products, capable of predicting myocardial infarction shock progression, expected within this year
Learn More -
Performance Validation of Boditech Med's AFIAS D-dimer in Thrombosis Research Journal
Superiority Demonstrated in Capillary Whole Blood and Venous Plasma Correlation Analysis
Learn More
Who We Are
Heading to Global Top 10 In-Vitro diagnostic Company, Boditech Med Inc
We Boditech Med have been focusing on developing key technologies of immune-diagnosis and molecular diagnosis to provide reliable In-Vitro diagnostic solutions for everyone at anywhere, and anytime.
We are constantly striving to become a global In-Vitro diagnostic company realizing the value of respect for life. And We wish to finally improve quality of life across the world.
Learn More